Ehrenkranz Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ehrenkranz Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,762	Closed	-$1.5M	–	53
2026 Q1	$1.5M	Buy	+11,762	New	+$1.47M	1.19%	13
2025 Q4	–	Sell	-163,193	Closed	-$16.4M	–	49
2025 Q3	$16.4M	Buy	+163,193	New	+$14.7M	14.34%	2

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Ehrenkranz Partners's XBI Position: Q2 2026 in Review

Ehrenkranz Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 11,762 shares — an estimated $1.5M sold.

Ehrenkranz Partners first reported a position in XBI in Q3 2025 and held it in 2 quarters. The position peaked at $16.4M in Q3 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Ehrenkranz Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
Ehrenkranz Partners sold 11,762 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.5M.
Ehrenkranz Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2025 and held it in 2 quarters.
Ehrenkranz Partners's State Street SPDR S&P Biotech ETF position peaked at $16.4M in Q3 2025.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Ehrenkranz Partners's 13F filing for Q2 2026, filed 14 Aug 2026.